Lozano, RebecaLorente, DavidAragon, Isabel MRomero-Laorden, NuriaNombela, PazMateo, JoaquimReid, Alison H MCendón, YleniaBianchini, DilettaLlacer, CasildaSandhu, Shahneen KSharp, AdamRescigno, PasqualeGarcés, TeresaPacheco, Maria IFlohr, PenelopeMassard, ChristopheLópez-Casas, Pedro PCastro, Elenade Bono, Johann SOlmos, David2025-01-072025-01-072021-05-122072-6694https://hdl.handle.net/10668/25067Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3-6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3-6 weeks (CTC conversion (from ≥5 toenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/PSAbiomarkerscirculating tumor cellsdocetaxelmetastatic castration-resistant prostate cancerresearch article34066080open access10.3390/cancers13102334PMC8151844https://www.mdpi.com/2072-6694/13/10/2334/pdf?version=1620819355https://pmc.ncbi.nlm.nih.gov/articles/PMC8151844/pdf